INTRODUCTION
In 2018, end stage renal disease (ESRD) remains a significant public health problem reaching a prevalence of over 700 000 in the US population alone, with nearly 500 000 individuals receiving maintenance dialysis therapy to survive [1, 2] . The presence of ESRD increases an individual's risk of death, particularly cardiovascular death, 10 to 30-fold compared to individuals with preserved kidney function [3, 4] . Traditional risk factors such as hypertension, atherosclerosis, and left ventricular hypertrophy are highly prevalent in ESRD and contribute to cardiovascular risk, yet studies employing conventional treatments such as angiotensin-converting enzyme inhibitors [5] and statins [6] have failed to change key outcomes in the ESRD population suggesting novel pathophysiology exists.
Human proteins, during both health and disease, are exposed to a variety of chemical reactions capable of altering their structural and functional properties. Spontaneous posttranslational protein modifications can occur through the nonenzymatic binding of reactive molecules to protein functional groups, as seen, for example, in glycation reactions which can increase because of hyperglycemia in diabetes mellitus. Protein carbamylation describes a posttranslational protein modification that is driven by cyanate, the reactive dissociation product of urea (Fig. 1) . Although generally found in low concentrations in vivo, urea, and thus cyanate and carbamylation, all naturally increase when kidney function declines. Protein carbamylation is not solely related to urea; it has also been shown that & ]. Protein carbamylation can therefore stem from such divergent exposures as kidney disease, diet, smoking, and air pollution, ultimately leading to common pathways of molecular and cellular dysfunction.
Because carbamylation is a protein modification that can result from exposure to urea and its byproduct, cyanate, it has become an increasing focus of nephrology research, particularly in the ESRD population. This report reviews our current understanding of the consequences of protein carbamylation in humans, followed by clinical studies of carbamylation in ESRD with attention to the possible therapeutic approaches being proposed.
CONSEQUENCES OF CARBAMYLATION
The net result of the carbamylation reaction is the addition of a ''carbamoyl'' moiety (-CONH 2 ) to a functional group (Fig. 1) ]. Although there appeared to be a basal level of carbamylation occurring in control mice without renal disease, there was a two-fold increase in carbamylation burden in 75% nephrectomized mice at 20 weeks across these tissues. Thus, at physiological conditions and normal kidney function, carbamylation still occurs, and proteins with long half-lives will accumulate the modification [14 && ]. Indeed, numerous disciplines beyond nephrology have implicated protein carbamylation in specific human disease processes such as cataract formation [15] [16] [17] , arthritis and autoimmune disease [18,19 & 
,20
& ], and neurological diseases [21, 22] . However, given the relationship between urea, cyanate, and decreased kidney function, the nephrology community may still hold the greatest interest. Carbamylation's link to mechanisms of cardiovascular disease (CVD) and erythropoietin (EPO) resistance are two particularly relevant examples why. 
Mechanisms of cardiovascular disease and outcomes

Erythropoietin resistance mechanisms and outcomes
Carbamylation of EPO abrogates its erythropoietic activity both in vitro and in vivo and thus, carbamylation of EPO or proteins in the erythropoietic pathway may directly contribute to the pathophysiology Pathways that promote the protein carbamylation reaction. Cyanate and its tautomer isocyanate can be derived from sources such as diet or smoking, and from urea which accumulates with impaired kidney function. The reactive species can carbamylate the N-terminal of a protein or an amino acid side chain. This reaction can also occur on free individual amino acids in a similar fashion. Carbamylated proteins may undergo change in charge, structure, and function leading to molecular and cellular dysfunction. MPO, myeloperoxidase.
of EPO resistance in CKD [33] . Indeed, we showed among 161 hemodialysis patients that study participants in the highest quartile of carbamylated albumin (a global marker of carbamylation burden analogous to hemoglobin A1C being a marker of glycemic control in diabetes) had the lowest hemoglobin levels, yet used the greatest recombinant EPO doses [34 && ]. Interestingly, increasing EPO resistance was associated with a higher risk of death as previously established by others [35] , yet the association between EPO responsiveness and mortality was no longer statistically significant when carbamylation was included in the analysis, as carbamylation showed the dominant association with death. This so-called ''hyporesponsiveness'' to EPO that independently associates with carbamylation (independent of traditional risks such as iron stores and inflammatory markers) has become a promising intermediary clinical end point in interventional studies that aim to ameliorate carbamylation levels in chronic dialysis patients (e.g., NCT02472834, see next section) [36 && ]. Changes in EPO responsiveness are likely to manifest on the order of months vs. the years it takes to chart differences in mortality. The detrimental, mechanistic effects of carbamylation stretch beyond the pathways discussed herein. From accelerating kidney fibrosis to triggering autoimmunity, the reader is directed to broader literature reviews of protein carbamylation [12
CLINICAL ASSOCIATION STUDIES OF CARBAMYLATION IN END STAGE RENAL DISEASE
The plasma concentration of cyanate in healthy individuals is about 45 nmol/l, and in patients with ESRD on dialysis it reaches 140 nmol/l [37] . Although this increase may seem mild, recall that urea dissociation is constantly generating more cyanate, which rapidly binds to nearby proteins and amino acids, and thus the rate of protein and amino acid carbamylation may become quite significant. Moreover, thiocyanate also elevates in ESRD patients, introducing another pathway by which carbamylation can accelerate in this population [38] [39] [40] . Kraus et al. [41] demonstrated that serum concentrations of many carbamylated free amino acids in patients with ESRD exceeded the concentrations of their unmodified precursors, a finding that could have implications for the nutritional depletion, specifically protein energy malnutrition, well described in ESRD patients [42] . Although it seems urea accumulation would play a dominant role in the carbamylation burden of patients with ESRD, comparative assessments of the relative impacts of amino acid balance or the myeloperoxidase catalyzed pathway on carbamylation have not been established.
Early studies looking at carbamylation burden in patients with ESRD requiring dialysis were partially motivated by identifying a reliable marker of dialysis adequacy. It was shown that carbamylated hemoglobin was negatively correlated with both Kt/V and urea reduction ratios [43] , and that carbamylated hemoglobin was a more accurate indicator of time-averaged urea than the conventional indices of dialysis adequacy [44, 45] . Notably, these studies did not ultimately test if carbamylation measures could predict clinical outcomes such as mortality better than the standard dialysis adequacy measures. However, in contemporary dialysis, we have found adequacy measures often fail to demonstrate a mortality association as most patients meet minimum recommendations and, unfortunately, doses beyond these requirements neither show significant survival benefit nor improvement in uremic toxin clearance [ Such findings reiterate that carbamylation should not be considered a simple urea equivalent, rather its levels likely integrate multiple pathologic pathways including nutritional status, inflammation, and time-averaged solute clearance and accumulation, making it a potent assessment of health risk.
In 2013, two groups independently and simultaneously reported on the all-cause mortality risk associated with elevated protein carbamylation levels in hemodialysis patients. It was noteworthy that the investigator groups were completely independent, used different measures of carbamylation burden (carbamylated albumin and protein-bound homocitrulline), and studied three distinct hemodialysis cohorts in total, each with unique attributes (incident dialysis, prevalent dialysis, and prevalent dialysis patients with diabetes). Even after adjusting for relevant covariates, in each of these cohorts, baseline protein carbamylation was found to be an independent risk factor for death in follow-up periods ranging from 1 to 5 years [7 && ,51 && ]. In the first of these studies, Koeth et al. [51 && ] looked at serum protein-bound homocitrulline levels in a group of 347 patients undergoing maintenance hemodialysis with 5 years of follow-up. After multivariable adjustments, carbamylation levels in the highest tertile conferred a more than double risk of death compared with patients with carbamylation levels in the middle or lowest tertiles. Nearly simultaneously, we reported similar findings using two distinct cohorts of hemodialysis patients [7 && ]. The first cohort consisted of 187 participants from the Accelerated Mortality on Renal Replacement cohort which included only incident dialysis patients followed for up to 1 year. Like the Koeth et al. [51 && ] study, we found a risk ratio 3.23; 95% confidence interval, 1.74-6.00 for the top tertile of carbamylation (measured using carbamylated albumin) compared with the lowest. In the largest hemodialysis cohort in which carbamylation has been studied, we employed data and blood samples from the randomized controlled ''German Diabetes and Dialysis study'' which investigated the benefits of the cholesterol-lowering drug atorvastatin in diabetic dialysis patients (n ¼ 1161) [6] . In this group of prevalent diabetic hemodialysis study participants, we again found a significant risk of death among study participants with the highest tertile of carbamylated albumin (hazard ratio, 2.25; 95% confidence interval, 1.42-3.56), even after multivariable adjustments [7 && ]. The actual cause of death in these carbamylation association studies next became of interest to shed light onto any mechanistic underpinnings from the findings. Drechsler et al. [52 && ] addressed this by reanalyzing the aforementioned German Diabetes and Dialysis study data. Carbamylated albumin levels were strongly associated with 1-year adjusted risk of cardiovascular mortality, sudden cardiac death, and the 4-year risk of death from congestive heart failure. This has been the only report of cause of death in ESRD in association with carbamylation to date and further work is required. Although it may seem at odds with the earlier studies in study participants with preserved renal function that strongly implicated carbamylation in pathways of atherosclerosis, ischemia, and need for revascularization, the differences in the patient populations (ESRD vs. largely preserved renal function) could account for this. It is reported that with declining kidney function, there is a progressive shift from ischemic to nonischemic causes of cardiac death, particularly sudden death in the absence of evidence of an acute myocardial infarction [2] . Notably, carbamylation also associated with cardiac stress markers and adverse long-term events in a smaller cohort of non-ESRD patients with chronic systolic heart failure [53] . The comparative rates of carbamylation-linked accelerated atherosclerosis vs. cardiomyopathy are unknown.
Another key observation that came of the post hoc study of the German Diabetes and Dialysis statin trial was that in subgroup analysis, study participants in the lowest carbamylation tertile appeared to derive a survival benefit from the cholesterol-lowering drug, whereas study participants in the second and top tertile of carbamylation showed no benefit from statin therapy [52 && ]. As the original trial showed that statins, one of the most potent and efficacious CVD risk modifiers in the general population, conferred no benefit to dialysis patients, detecting a signal of benefit in an ESRD subgroup is noteworthy. It is plausible that a statin benefit is only evident in patients free from the competing risk of excessive carbamylation, which may be a comparatively stronger risk factor. This hypothesis needs additional work to determine its merit. For example, it remains unclear what effect a patients' carbamylated low density lipoprotein (LDL) levels have on the net efficacy of statin therapy. Perhaps greater carbamylated LDL modifies the typical beneficial effects of statin therapy seen in non-ESRD patients. If true, this could potentially introduce a new therapeutic target in the ESRD population (either the reduction of global carbamylation load or carbamylated LDL specifically).
Interest in reducing protein carbamylation burden further increased when we began to better understand the natural history of carbamylation in ESRD overtime. In another case-control study of 122 incident ESRD hemodialysis study participants who survived at least the first 90 days of dialysis but died within 1 year (cases) and 244 incident dialysis patients who survived beyond 1 year (controls), carbamylated albumin levels measured at the start of dialysis and every 90-day period until 1 year or death, showed that at the time of dialysis initiation, carbamylation levels in both groups were markedly higher than levels observed in prevalent maintenance dialysis [50
&&
]. This suggests that as CKD progresses and before dialysis restores some degree of solute clearance, patients are likely in a ''peak'' carbamylation state. Nevertheless, the high levels of carbamylation at dialysis initiation were similar between the cases and controls. Adjusted repeated measures analysis of carbamylation changes over time then showed that 1-year survivors experienced a significantly greater mean carbamylation decrease from baseline compared with cases. Interestingly, similar analysis of urea levels, serum albumin, or standard dialysis metrics such a Kt/V or normalized protein catabolic rate did not show any differences between the groups. This implies that a greater reduction in carbamylation over time is associated with a lower risk of mortality and this is a phenomenon independent of traditional risk factors. Indeed, multiple studies aimed at understanding how carbamylation can be modulated seek to prove such a benefit.
POSSIBLE TARGETED THERAPIES TO MITIGATE CARBAMYLATION IN KIDNEY DISEASE
Given the associations between carbamylation and poor clinical outcomes, focus has turned to determining precisely how to modulate carbamylation. Nutritional interventions and dialysis modifications have been the two most promising avenues studied thus far. The transition from late stage CKD not on dialysis to ESRD on maintenance dialysis has been shown to confer a substantial reduction in protein carbamylation presumably from substantial lowering of circulating urea levels [50 && ]. However, maintenance hemodialysis remains a state of excess carbamylation relative to healthy controls and studies looked if more hemodialysis (i.e., extended duration) might reduce carbamylation levels. Study participants receiving routine thrice weekly hemodialysis who converted to extended duration (double treatment time), thrice weekly, in-center hemodialysis showed significant reduction in protein carbamylation compared with a nonrandomized control group that did not change from its conventional dialysis prescription [54 && ]. This study went on to show that individuals who experienced the greatest reductions in carbamylation in the extended dialysis group also demonstrated reductions in left ventricular mass as assessed by cardiac MRI. Also noteworthy was study participants undergoing the intensive dialysis strategy demonstrated an increase in serum amino acid levels, possibly related to nutritional improvements in the more dialyzed patients. Given the background mechanisms of elevated urea driving increases in cyanate and carbamylation, and the demonstration that serum-free amino acid levels effectively compete with proteins for carbamylation, the mechanisms may have acted together to produce the observed reduction in carbamylation.
The notion of elevating circulating amino acid levels to effectively shield proteins from carbamylation has been more directly studied as well. Based on in-vitro and animal studies demonstrating that amino acid supplementation can reduce protein carbamylation load in the presence of urea or cyanate [7 && ], in-human studies of amino acid supplementation during hemodialysis are being pursued. We reported the first proof-of-concept investigation of amino acid therapy aimed at reducing carbamylation in a small pilot study of hemodialysis study participants [36 && ]. Carbamylated albumin levels measured across an 8-week period (two half-lives of normal serum albumin) fell by 15% in individuals receiving a commercially available amino acid infusion during routine thrice weekly dialysis treatments when compared with individuals receiving no treatment. Notably, there was not an appreciable change in blood urea levels in the treated group which was a concern given the additional nitrogen load amino acids carry as it could counter carbamylation decreases. Although such results are promising, it is important to note that no study has yet examined if the modulation of carbamylation will result in actual changes in clinical outcomes. This point is being addressed through an ongoing randomized controlled clinical trial examining amino acid therapy on hemodialysis to reduce carbamylation and assess intermediary clinical end points such as changes in EPO responsiveness (NCT02472834).
Amino acid strategies were also studied in a post hoc analysis from a peritoneal dialysis trial which originally compared the metabolic effects of lowglucose peritoneal dialysis solutions (incorporating icodextrin and intraperitoneal amino acids) with a control group (dextrose-only solutions) [55
Researchers examined the impact the two treatment strategies had on carbamylation levels. First, this report noted that when carbamylated albumin levels of diabetic peritoneal dialysis patients were compared with matched hemodialysis study participants, peritoneal dialysis patients had significantly higher baseline urea levels and higher carbamylated albumin levels (mean AE SD: urea, 58.6 AE 16.7 vs. 48.4 AE 15.2 mg/dl; carbamylated albumin, 11.4 AE 4.0 vs. 10.1 AE 4.1 mmol/mol). Among the peritoneal dialysis study participants, there was no difference in carbamylation change in either arm, but amino acid-treated study participants showed a trend toward increased carbamylation. Notably, the treated study participants also demonstrated an increase in urea, possibly explaining the carbamylation trend. These data suggest intraperitoneal amino acid treatment might not be efficacious to reduce carbamylation in this population [55 && ]. Additional therapeutic insights were gained through a well-designed and rigorous study of dietary modifications to modulate carbamylation. Di Iorio et al. [56 && ] achieved significant carbamylation reductions through dietary interventions employing either a very low protein diet supplemented with ketoanalogues (VLPD þ KA) or a Mediterranean diet, compared with a free diet. After 6 months on a given diet intervention, when compared with free diet, both Mediterranean diet and VLPD were associated with a decrease in carbamylation levels. Although urea reduction is presumably the primary effect these dietary interventions had on carbamylation, it is notable that the VLPD þKA showed the most dramatic carbamylation reduction and the impact of ketoanalogues supplementation on circulating amino acids is not entirely known. In many ways, this study corroborates the studies in dialysis that suggest urea reduction and amino acid supplementation (without increasing urea) as effective strategies to reduce carbamylation. To date, there have not been association studies linking carbamylation to clinical outcomes in a CKD cohort not on dialysis. Finally, in-vitro and animal studies have shown additional potential through drugs that appear to shield proteins from carbamylation including ascorbic acid [57] , flavonoids [58] , eicosapentaenoic acid [59] , ibuprofen [60] , aspirin [61] , bendazac [62] , and triclosan [63] . Translation of these bench experiments to possible clinical applications is yet to occur.
CONCLUSION
Decades of basic science work have created a rich literature demonstrating how protein carbamylation could be mechanistically linked to the novel pathophysiology of ESRD. Observational studies persuasively show that protein carbamylation is an independent risk factor for adverse clinical outcomes in patients with ESRD on dialysis including mortality. The mediators of carbamylation appear diffuse, but include elevations in blood urea levels and decrements in circulating amino acid levels. Interventions to reduce urea load and restore amino acid balance appear the most promising, thus far, at reducing systemic carbamylation burden. However, the uremic milieu is exceedingly complex and the net clinical impact of such maneuvers still needs further investigation prior to changing practice.
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